Extended Release Drug Delivery System: A Review

Kothawade vishal S.* , Patil Prashant B.
Department of Pharmaceutics, R. G. Sapkal College Of Pharmacy, Trimbakeshwar Road, Nashik- 422012, Dist-Nashik (MH) India

ABSTRACT:
The drawn out release dosage forms enjoy numerous benefits in wellbeing and adequacy over immediate release items in that recurrence of dosing can be diminished drug adequacy can be drawn out and the frequency of unfriendly impacts can be diminished. Extended release drug formulations have been utilized since 1960's. These formulations make the drug accessible throughout extended time-frame after oral administration. Extended release drug delivery framework which decrease the dosing recurrence of specific drugs by delivering the drug gradually throughout an extended timeframe. There are different physiochemical and organic properties which influence the extended release drug delivery framework. This article giving the new literature in regards to advancement and plan of extended release tablets.
KEYWORDS: Extended release, Extended Release Drug Delivery System,Half Life, Absorption.

I. INTRODUCTION:
Lately in relationship with progress and innovation in the field of pharmaceutical technology there has been an expanding work to foster prolonged release dosage forms. The prolonged release dosage forms enjoy many benefits in security and adequacy over immediate release items in that recurrence of dosing can be diminished drug viability can be prolonged and the rate of unfriendly impacts can be diminished. Extended release drug formulations have been utilized since 1960's. These formulations make the drug accessible throughout extended time span after oral organization. The extended release item will optimize therapeutic impact and security of a drug simultaneously works on understanding comfort and consistence, by fusing the portion in a unit dosage form from which the drug is gradually released for 24 hr. This formulation assists with staying away from the incidental effects related with low fixation and high focuses. The best drug conveyance framework should show a steady zero-request release rate and keep up with the consistent plasma fixations[1].

ADVANTAGES:
I. The extended release formulations keep up with therapeutic focuses over prolonged periods.
II. The utilization of extended release formulations stays away from the high blood focus.
III. Extended release formulations can possibly work on the patient consistence.
IV. Lessen the poisonousness by easing back drug ingestion.
V. Increment the stability by shielding the drug from hydrolysis or other degradative changes in gastrointestinal tract.
VI. Limit the neighborhood and fundamental incidental effects.
VII. Improvement in treatment efficacy.
VIII. Least drug use.
IX. Improvement the bioavailability of certain drugs. Ex: Divalproex sodium
X. Improvement of the capacity to give embellishments.
Eg: Morning alleviation of arthritis through bed time dosing[2].

DISADVANTAGES:
I. Significant expense of readiness.
II. The release rates are influenced by different factors such as, food and the rate travel through the gut.
III. Extended release formulation contains a higher drug burden and consequently any deficiency of respectability influences the release attributes of the dosage form.
IV. The bigger size of extended release items may cause challenges in ingestion or travel through gut.
V. Decreased potential for dosage change.

FACTORS AFFECTING EXTENDEDRELEASE DRUG DELIVERY SYSTEM

1. Physicochemical properties of drug:

A) Aqueous Solubility:

As the drug should be in arrangement form before retention, drug having low aqueous solubility generally suffers oral bioavailability issue because of restricted GI transit season of un-broke up drug and restricted solubility at ingestion site. So these sorts of drug are unfortunate. Drug having outrageous aqueous solubility are bothersome for ER since, it is too hard to even think about controlling release of drug from the dosage form. Physiological pH subordinate solubility for example variety in solubility at different GI pH are unwanted (for example Aspirin, which is less dissolvable in stomach, yet more solvent in intestine) as it will yield variety in dissolution rate. A drug with great aqueous solubility, pH free solubility is alluring for oral new drug delivery framework[3].

b) Partition co-efficient:

As biological membrane is lipophilic in nature through which the drug needs to pass however, so parcel co-efficient of drug impact the bioavailability of drug very a lot. Drug having lower parcel co-efficient qualities not exactly the ideal action are unwanted for oral ER drug delivery framework, as it will have very less lipid solubility and the drug will be limited at the primary aqueous stage it come in contact for example Barbituric acid. Drug having higher parcel co-efficient worth greater than the ideal movement are unwanted for oral ER drug delivery framework on the grounds that more lipid solvent drug won't segment out of the lipid membrane once it gets in the membrane. The ideal n-octanol/water segment coefficient at which greatest flux happens is around 1000.

c)Drug stability in vivo:

As the majority of ER Drug delivery framework is planning to release drug over the length of the GIT, henceforth drug ought to be steady in GI environment. So drug, which is unsteady, can't be formulated as oral ER drug delivery framework, as a result of bioavailability issue. for example - Nitro-glycerine.

d) protein binding:

Drug protein restricting impacts the appropriation balance of drugs. Plasma proteins exert a buffer work in the attitude of drugs, especially appropriation; the disposal half-life of the drugs will be long, and they may not be able to be formulated into controlled release dosage forms.

Only the free, nonprotein-bound part of the drug can diffuse into the tissue from the blood vessels. The balance among free and bound drug goes about as a buffer system and keeps a relatively constant concentration of the drug over an extensive stretch of time through the dissociation of the drug protein complex[4].

e) Drug pKa & Ionization at physiological pH:

As we probably are aware just unionized drug are absorbed and permeation of ionized drug is immaterial, since its pace of absorption is 3 to multiple times not exactly that of the unionized drug. pKa range for acidic drug where ionization is pH delicate is around 3.0 – 7.5 and pKa range for fundamental drug whose ionization is pH delicate is around 7.0-11.0 are ideal for ideal positive absorption. Drug will be unionized at the site to an extent 0.1 - 5.0%. Drugs existing generally in ionized structure are helpless contender for oral ER drug delivery framework. e.g.:- Hexamethonium.

f) Mechanism and sit of absorption:

Drug absorption via carrier interceded transport and those absorbed through a window are helpless contender for oral ER drug delivery framework for example – several B vitamins. Drugs absorbed by passive diffusion, pore transport and through over the whole length of GIT are appropriate possibility for oral ER drug delivery framework.

g) Molecular Size and diffusivity:

The arrival of solute or its diffusivity in a polymer is regularly a complex motor parameter that is determined by the properties of the solute like size and shape and the properties of the polymer. Generally, if permeation happens by means of the pore component (i.e., through water-filled pores), the solute size will importantly affect diffusivity. However, permeation through the segment system is less solute-size subordinate. Solute diffusion coefficients in cross-connected polyacrylamide and polyvinylpyrolidone gel show a logarithmic reliance on embed polymer fixation and solute atomic weight. Drug sub-atomic loads under 500 Dalton don't create issues with drug absorption and henceforth might be reasonable for oral controlled drug delivery[5].

h) Dose size-size:

On the off chance that an item has dose size >0.5g it is a helpless contender for oral ER drug delivery framework, since expansion in main part of the drug, in this way builds the volume of the item.

2. Biological properties of drug:
A) Absorption:
For oral ER drug conveyance framework the pace of drug absorption (ka) ought to be more than that of the pace of drug discharge (kr) from the dosage structure for example kr <<< ka. Drug that are gradually assimilated or consumed with a variable absorption rate are helpless possibility for oral ER drug conveyance framework. Some potential purposes behind a low degree of absorption are helpless water solubility, little partition co-efficient, corrosive hydrolysis, and metabolism or its site of absorption.

b) Distribution:
Drugs with high clear volume of distribution, which impact the pace of end of the drug, are helpless contender for oral ER drug conveyance framework for example Chloroquine.

c) Metabolism:
Drug, which broadly metabolized isn't reasonable for ER drug conveyance framework. A drug equipped for inciting metabolism, restraining metabolism, metabolized at the site of absorption of first-pass impact is helpless contender for ER conveyance, since it very well may be hard to keep up with constant blood level for example levodopa, nitroglycerine[6].

d) Half-life of drug:
A drug having organic half-life between 2 to 8 hours is most appropriate for oral ER drug conveyance framework. As though organic half-life < 2hrs the framework will require inadmissibly enormous rate and huge portion needed to keep up with study state and drug with natural half-life >8 hours, formulation of such drug into oral ER drug conveyance framework is superfluous.

e) Margin of safety:
As we probably are aware bigger the worth of helpful list more secure is the drug. Drugs with less helpful list generally helpless contender for formulation of oral ER drug conveyance framework.

f) Plasma concentration response relationship:
By and large pharmacological response of drug relies upon plasma drug concentration instead of size and dose. Yet, a few drugs pharmacological action is free of plasma concentrations, which are helpless possibility for oral ER drug conveyance system E.g. Reserpine.

APPROACHES TO ACHIEVE EXTENDED RELEASE DRUG DELIVERY
The reason for designing ER dosage form is to foster a solid formulation that enjoys every one of the benefits of immediate release dosage form but then without the portion unloading. Different techniques have been utilized in the formulation of ER products. In general, expanded formulations can be separated into different classifications dependent on the mechanism of drug release[7,8].
1) Dissolution Controlled Release
2) Diffusion Controlled Release
3) Ion Exchange Resins Controlled Release
4) Swelling Controlled Release.

1)Dissolution Controlled Release:
This kind of controlled release includes two cycles, the unit of drug molecules from the surface of their solid construction to the contiguous liquid interface, trailed by their diffusion from the interface into the bulk liquid medium. The rate of dissolution and the amount disintegrated per unit of time from this framework can be determined utilizing Noyes-Whitney equation which relates the rate of dissolution of solids to the properties of the solid and the dissolution medium, and the connection is given by:

$$dW/dtL = DA (Cs - C)$$

Where,
dW/dt is the rate of dissolution;
A is the surface area of the solidification;
C is the concentration of the solid in the bulk dissolution medium;
Cs is the concentration of solid in the diffusion layer surrounding the solid;
D is the diffusion coefficient and
L is the diffusion layer thickness.

2)Diffusion Controlled release:
This kind of controlled release system, the active ingredient diffuses through the polymeric material. These are mainly classified as reservoir and matrix systems[9,10].

a)ReservoirSystem:
Cellulosederivativesareordinarilyutilizedin thereservoirsystems.Itcomprisesofacenter(thereservoir)andcoatingmembrane(thediffusionbarrier).Theactiveingredientdiffusesfromthereservoirthroughthecoatingmembrane.
Forareservoirsystemwherethedrugstationisencircledbyapolymerichydrogelmembrane,Fick'sfirstlawofdiffusioncanbeutilizedtodepictdrugreleasethroughthemembrane[9,10].

b) Matrix System:
In this review article greater accentuation is given for matrix controlled release for plan of extended release tablets. A matrix system comprises of active and inactive ingredients that

are homogeneously dispersed and blended in the measurement form. It is by a wide margin the most normally utilized oral extended release innovation and the ubiquity of the matrix systems can be ascribed to several factors. The release from matrix type formulations is governed by Fick's first law of diffusion[11,12,13].

3) Ion Exchange Resins Controlled Release:

Ion Exchange resins are cross-linked water-insoluble polymers conveying ionizable functional gatherings. The resins have been utilized in different drug applications, principally for taste concealing and controlled release systems. In tablet formulations, ion trade resins have been utilized as disintegrant, due to their swelling ability. It forms irreversible complex with ionizable drugs upon delayed openness of the drug to the resin. A resin bound-drug is taken out when fitting ions are in touch with ion-exchanged gatherings. The region and length of diffusion pathway, and the amount of cross-linked polymer in the resin moiety governs the rate of drug release.

4) Swelling Controlled Release:

Expanding controlled systems depend on growing of ER polymer. Due to the viscoelastic properties of the polymers, which are upgraded by the presence of cross-connected organization, anomalous penetrate transport can be observed. This conduct is bound by unadulterated Fickian diffusion and case II transport. Therefore, transport can be decreased to three main impetuses. The penetrate concentration gradient, polymer concentration gradient and osmotic power conduct are observed because of polymer organization. Proper polymer can counterbalance ordinary Fickian diffusion by hindering the release of implanted drug, prompting an extended period of drug delivery, and conceivably zero-order release[14].

II. CONCLUSION:

We finished up from the above conversation that extended release formulations are very much accommodating in expanding the viability of the drugs with short half life and furthermore work on persistent consistence by diminishing the dosing recurrence. Presently, a wide scope of drugs are formulated in a wide range of oral extended release measurements forms. However, just those which bring about a critical decrease in portion recurrence and a decrease in toxicity coming about because of high concentration in the blood or gastrointestinal plot are probably going to work on therapeutic results. To be a fruitful extended release item, the drug should be released from the measurements form at a predetermined rate, disintegrate in the gastrointestinal liquids, keep up with adequate gastrointestinal home time, and might be assimilated at a rate and will supplant the amount of drug being metabolized and excreted.

REFERENCES:
[1]. Madhusudhan P, Nazeer S, Extended Release Formulation, International Journal Of Pharmacy & Technology, 2(4), Dec-2010, 625- 684.

[2]. Herbert A. Lieberman, Leon Lachman and Joseph B. Schwartz, Sustained Drug Release from Tablets and Particles through Coating. In Pharmaceutical dosage forms Tablets, Second Edition, Revised and Expanded, volume 3, Marcel Dekker, 1990, 199- 213.

[3]. Joseph R. Robinson and Vincent H. L. Lee, Influence of drug properties and routes of drug administration on the design of sustained and controlled release system. In Controlled drug delivery, Marcel Dekker, New York, 1978, 13-36.

[4]. Gilbert S. Banker and Christopher T. Rhodes, Sustained and controlled release drug delivery system. In Morden Pharmaceutics, Fourth Edition, Revised and Expanded, Marcel Dekker, New York, 2002, 11.

[5]. D. M. Brahmankar and Sunil B. Jaiswal, Controlled release mechanism. In Biopharmaceutics and Pharmacokinetics A-Treatise, Vallabh prakashan, Nagpur, 1995, 335-354.

[6]. Howard C. Ansel, PhD, Nicholas G. Popovich, PhD and Loyd V. Allen, Jr., PhD, Solid oral modified- release dosage form and drug delivery system. In Pharmaceutical Dosage Forms and Drug Delivery Systems, Lippincott Williams & Wilkins, a Wolters Kluwer business, Ninth Edition, 2005, 257-260.

[7]. Kamboj S, Jagmohan oberoy and Gupta G D. Matrix Tablets: An Important Tool for Oral Controlled- Release Dosage Forms. Pharmainfo net. 2009.

[8]. Lloyd N. Sansom, Head school of pharmacy and medical science, University of south

Australia, Adelaide. In oral Extended release product. Australian prescriber, 1999.

[9]. Tapash K. Ghosh and Bhaskara R. Jasti, Oral Controlled Release Solid DosageForms. In Theory and Practice of Contemporary Pharmaceutics, CRC press boca raton London, New York Washington, D.C. 2005, 339-342.

[10]. H. Steckel, F. Mindermann-Nogly, Production of chitosanpellets by extrusion/spheronization, European Journal ofPharmaceutics and Biopharmaceutics, 57, 2004, 107–114.

[11]. P.B. Deasy , M.F.L. Law Use of extrusion-spheronization to develop an improved oral dosage form of indomethacin, International Journal of Pharmaceutics 148 (1997) 201-209

[12]. Robinson J R, Lee V H L, Controlled drug delivery "Fundamentals and application", Informa Healthcare, 20, 2009, 373-421.

[13]. Verma R K, Krishna D M, Garg S, Formulation aspects in the development of osmotically controlled oral drug delivery systems, Journal of Controlled Release, 2002, 79, 7-27.

[14]. Raizada A, Bandari A, Kumar B, Polymers in drug delivery: A review, International Journal of Pharma. Research and Development, 2(8), 2010, 9-20.